| Summary: | 碩士 === 國立交通大學 === 生物科技系所 === 97 === Dendritic cell (DC)-based antitumor vaccine is a promising immunotherapy for cancer in recent years. However, the clinical results in the clinical trails showed that
the treatments of DC vaccines benefit only a subset of patients to result in tumor regression. One possible explanation has been suggested that many malignant tumors
would secrete immunosuppressive factors such as TGF-β1, which is possible to limit the efficacy of the DC-based vaccine by suppressing the host immune responses. In
this study, we demonstrated that delivering an immuno-modulated gene into cells and fusing cells simultaneously could improve the efficacy of DC fusion vaccine.
IL-6, an antagonist against the immunosuppressive activity of TGF-β1, was used as the transgene in this study. In addition, LPPC, a novel cationic liposome, plays the
role in the co-transfection during fusion process. The results showed that the addition of LPPC didn’t interfere with the fusion efficiency of PEG and it indeed transfected
simultaneously the IL-6 gene into the cells during the fusion process. Consistently, animals vaccinated with LPPC/IL-6/PEG DC vaccines elicit superior immunogenic
effects. Therefore, this strategy may have the potential to be a promising strategy for gene-modified DC fusion vaccine in the clinical use.
|
|---|
